Accordingly, this study is aimed at comparing the efficacy and safety of gemigliptin add-on versus metformin dose escalation in patients with T2DM inadequately controlled using metformin and SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.